tetano
Editor, Senior Moderator
Nat Commun
. 2022 Oct 23;13(1):6309.
doi: 10.1038/s41467-022-33985-4.
Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine
Dapeng Li[SUP] 1 2 [/SUP], David R Martinez[SUP] 3 [/SUP], Alexandra Schäfer[SUP] 3 [/SUP], Haiyan Chen[SUP] 1 2 [/SUP], Maggie Barr[SUP] 1 [/SUP], Laura L Sutherland[SUP] 1 [/SUP], Esther Lee[SUP] 1 2 [/SUP], Robert Parks[SUP] 1 [/SUP], Dieter Mielke[SUP] 4 [/SUP], Whitney Edwards[SUP] 1 [/SUP], Amanda Newman[SUP] 1 2 [/SUP], Kevin W Bock[SUP] 5 [/SUP], Mahnaz Minai[SUP] 5 [/SUP], Bianca M Nagata[SUP] 5 [/SUP], Matthew Gagne[SUP] 6 [/SUP], Daniel C Douek[SUP] 6 [/SUP], C Todd DeMarco[SUP] 1 2 [/SUP], Thomas N Denny[SUP] 1 2 [/SUP], Thomas H Oguin 3rd[SUP] 1 2 [/SUP], Alecia Brown[SUP] 1 2 [/SUP], Wes Rountree[SUP] 1 2 [/SUP], Yunfei Wang[SUP] 1 2 [/SUP], Katayoun Mansouri[SUP] 1 [/SUP], Robert J Edwards[SUP] 1 2 [/SUP], Guido Ferrari[SUP] 1 4 [/SUP], Gregory D Sempowski[SUP] 1 2 [/SUP], Amanda Eaton[SUP] 1 4 [/SUP], Juanjie Tang[SUP] 7 [/SUP], Derek W Cain[SUP] 1 2 [/SUP], Sampa Santra[SUP] 8 [/SUP], Norbert Pardi[SUP] 9 [/SUP], Drew Weissman[SUP] 10 [/SUP], Mark A Tomai[SUP] 11 [/SUP], Christopher B Fox[SUP] 12 [/SUP], Ian N Moore[SUP] 5 [/SUP], Hanne Andersen[SUP] 13 [/SUP], Mark G Lewis[SUP] 13 [/SUP], Hana Golding[SUP] 7 [/SUP], Robert Seder[SUP] 6 [/SUP], Surender Khurana[SUP] 7 [/SUP], Ralph S Baric[SUP] 3 [/SUP], David C Montefiori[SUP] 1 4 [/SUP], Kevin O Saunders[SUP] 14 15 16 17 [/SUP], Barton F Haynes[SUP] 18 19 20 [/SUP]
Affiliations
Abstract
Coronavirus vaccines that are highly effective against current and anticipated SARS-CoV-2 variants are needed to control COVID-19. We previously reported a receptor-binding domain (RBD)-sortase A-conjugated ferritin nanoparticle (scNP) vaccine that induced neutralizing antibodies against SARS-CoV-2 and pre-emergent sarbecoviruses and protected non-human primates (NHPs) from SARS-CoV-2 WA-1 infection. Here, we find the RBD-scNP induced neutralizing antibodies in NHPs against pseudoviruses of SARS-CoV and SARS-CoV-2 variants including 614G, Beta, Delta, Omicron BA.1, BA.2, BA.2.12.1, and BA.4/BA.5, and a designed variant with escape mutations, PMS20. Adjuvant studies demonstrate variant neutralization titers are highest with 3M-052-aqueous formulation (AF). Immunization twice with RBD-scNPs protect NHPs from SARS-CoV-2 WA-1, Beta, and Delta variant challenge, and protect mice from challenges of SARS-CoV-2 Beta variant and two other heterologous sarbecoviruses. These results demonstrate the ability of RBD-scNPs to induce broad neutralization of SARS-CoV-2 variants and to protect animals from multiple different SARS-related viruses. Such a vaccine could provide broad immunity to SARS-CoV-2 variants.
. 2022 Oct 23;13(1):6309.
doi: 10.1038/s41467-022-33985-4.
Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine
Dapeng Li[SUP] 1 2 [/SUP], David R Martinez[SUP] 3 [/SUP], Alexandra Schäfer[SUP] 3 [/SUP], Haiyan Chen[SUP] 1 2 [/SUP], Maggie Barr[SUP] 1 [/SUP], Laura L Sutherland[SUP] 1 [/SUP], Esther Lee[SUP] 1 2 [/SUP], Robert Parks[SUP] 1 [/SUP], Dieter Mielke[SUP] 4 [/SUP], Whitney Edwards[SUP] 1 [/SUP], Amanda Newman[SUP] 1 2 [/SUP], Kevin W Bock[SUP] 5 [/SUP], Mahnaz Minai[SUP] 5 [/SUP], Bianca M Nagata[SUP] 5 [/SUP], Matthew Gagne[SUP] 6 [/SUP], Daniel C Douek[SUP] 6 [/SUP], C Todd DeMarco[SUP] 1 2 [/SUP], Thomas N Denny[SUP] 1 2 [/SUP], Thomas H Oguin 3rd[SUP] 1 2 [/SUP], Alecia Brown[SUP] 1 2 [/SUP], Wes Rountree[SUP] 1 2 [/SUP], Yunfei Wang[SUP] 1 2 [/SUP], Katayoun Mansouri[SUP] 1 [/SUP], Robert J Edwards[SUP] 1 2 [/SUP], Guido Ferrari[SUP] 1 4 [/SUP], Gregory D Sempowski[SUP] 1 2 [/SUP], Amanda Eaton[SUP] 1 4 [/SUP], Juanjie Tang[SUP] 7 [/SUP], Derek W Cain[SUP] 1 2 [/SUP], Sampa Santra[SUP] 8 [/SUP], Norbert Pardi[SUP] 9 [/SUP], Drew Weissman[SUP] 10 [/SUP], Mark A Tomai[SUP] 11 [/SUP], Christopher B Fox[SUP] 12 [/SUP], Ian N Moore[SUP] 5 [/SUP], Hanne Andersen[SUP] 13 [/SUP], Mark G Lewis[SUP] 13 [/SUP], Hana Golding[SUP] 7 [/SUP], Robert Seder[SUP] 6 [/SUP], Surender Khurana[SUP] 7 [/SUP], Ralph S Baric[SUP] 3 [/SUP], David C Montefiori[SUP] 1 4 [/SUP], Kevin O Saunders[SUP] 14 15 16 17 [/SUP], Barton F Haynes[SUP] 18 19 20 [/SUP]
Affiliations
- PMID: 36274085
- DOI: 10.1038/s41467-022-33985-4
Abstract
Coronavirus vaccines that are highly effective against current and anticipated SARS-CoV-2 variants are needed to control COVID-19. We previously reported a receptor-binding domain (RBD)-sortase A-conjugated ferritin nanoparticle (scNP) vaccine that induced neutralizing antibodies against SARS-CoV-2 and pre-emergent sarbecoviruses and protected non-human primates (NHPs) from SARS-CoV-2 WA-1 infection. Here, we find the RBD-scNP induced neutralizing antibodies in NHPs against pseudoviruses of SARS-CoV and SARS-CoV-2 variants including 614G, Beta, Delta, Omicron BA.1, BA.2, BA.2.12.1, and BA.4/BA.5, and a designed variant with escape mutations, PMS20. Adjuvant studies demonstrate variant neutralization titers are highest with 3M-052-aqueous formulation (AF). Immunization twice with RBD-scNPs protect NHPs from SARS-CoV-2 WA-1, Beta, and Delta variant challenge, and protect mice from challenges of SARS-CoV-2 Beta variant and two other heterologous sarbecoviruses. These results demonstrate the ability of RBD-scNPs to induce broad neutralization of SARS-CoV-2 variants and to protect animals from multiple different SARS-related viruses. Such a vaccine could provide broad immunity to SARS-CoV-2 variants.